pentoxifylline sr tablet (extended-release)
aa pharma inc - pentoxifylline - tablet (extended-release) - 400mg - pentoxifylline 400mg - hemorrheologic agents
pentoxifylline tablet, extended release
nucare pharmaceuticals,inc. - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline extended-release tablets can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline extended-release tablets should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
pentoxifylline tablet, extended release
major pharmaceuticals - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
pentoxifylline tablet, extended release
state of florida doh central pharmacy - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablet is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline extended-release tablet can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline extended-release tablet should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
ratio-pentoxifylline tablet (extended-release)
ratiopharm inc division of teva canada limited - pentoxifylline - tablet (extended-release) - 400mg - pentoxifylline 400mg - hemorrheologic agents
pentoxifylline- pentoxifylline tablet, extended release
preferred pharmaceuticals, inc. - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
pentoxifylline tablet, extended release
aidarex pharmaceuticals llc - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets, usp are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
pentoxifylline tablet, extended release
nucare pharmaceuticals, inc. - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
pentoxifylline tablet, extended release
remedyrepack inc. - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.
pentoxifylline tablet, extended release
golden state medical supply, inc. - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.